Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. IQV
IQV logo

IQV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
180.144
Open
178.120
VWAP
173.98
Vol
1.60M
Mkt Cap
28.69B
Low
170.880
Amount
278.02M
EV/EBITDA(TTM)
12.36
Total Shares
167.87M
EV
42.40B
EV/OCF(TTM)
15.98
P/S(TTM)
1.82
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
Show More

Events Timeline

(ET)
2026-02-25
07:30:00
Iqvia Acquires Discovery Services Assets from Charles River Laboratories
select

News

seekingalpha
6.0
03-06seekingalpha
Barclays Upgrades IQVIA and Medpace Ratings Amid AI Concerns
  • Rating Upgrade: Barclays upgraded IQVIA (IQV) and Medpace (MEDP) from Equal-weight to Overweight, asserting that concerns over AI's impact on contract research organizations (CROs) are overstated, thus presenting attractive entry points for both short-term and long-term investors.
  • Stock Performance: Over the past 12 months, Medpace's stock has plummeted by over 46%, while IQVIA has seen a decline of more than 5%, with analysts believing that the sell-off has reset valuations to appealing levels suitable for investor entry.
  • Competitor Downgrades: Barclays downgraded Avantor (AVTR) and Pacific Biosciences (PACB) to Underweight, indicating limited upside potential for these companies and suggesting that it may take time for them to catch up as their turnaround stories unfold gradually.
  • Market Outlook: While AI is perceived to have a greater impact on CROs, analysts believe fears regarding AI disruption are exaggerated, and both IQVIA and Medpace stocks remain attractive, especially as Medpace's valuation has meaningfully returned to normal levels.
Barron's
8.0
03-05Barron's
Prescription Medication Costs Can Be Overwhelming: Tips for Finding the Best Prices.
  • Challenges in Drug Coverage: Navigating drug coverage in the current retirement system is complex and requires significant effort and understanding from individuals.

  • Increasing Difficulty: The process of managing drug coverage is becoming increasingly challenging, highlighting the need for better resources and support for retirees.

Newsfilter
1.0
03-02Newsfilter
IQVIA Executive to Speak at Barclays Healthcare Conference
  • Executive Speaking Engagement: IQVIA's CFO Mike Fedock is scheduled to speak at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026, at 9:30 AM ET, highlighting the company's leadership in the healthcare sector.
  • Live Webcast Availability: The presentation will be available via live audio webcast on the IQVIA Investor Relations website, with a replay accessible later that day, ensuring timely access to key information for investors and stakeholders.
  • Company Background Overview: IQVIA is a leading global provider of clinical research services with approximately 93,000 employees, dedicated to accelerating the development and commercialization of innovative medical treatments through high-quality health data and advanced analytics.
  • Privacy Protection Commitment: IQVIA is at the forefront of protecting patient privacy, utilizing a variety of privacy-enhancing technologies to ensure compliance with stringent privacy and safety standards while analyzing health data.
Newsfilter
8.5
02-27Newsfilter
IQVIA Releases 2025 Sustainability Report Highlighting Key Innovations
  • Employee Investment: In 2025, IQVIA expanded AI and data analytics training, generating over 230,000 employee engagements and involving more than 2,000 in leadership development programs, thereby enhancing its global leadership pipeline and exceeding Fortune 500 engagement benchmarks.
  • AI and Technology Innovation: IQVIA advanced its AI strategy by expanding key partnerships and launching new AI solutions, ensuring compliance in privacy and patient safety, which further solidifies its technological leadership in the healthcare sector.
  • Healthcare Accessibility: In 2025, IQVIA activated clinical trial sites in Brazil and Argentina, enrolling 5,700 participants towards a global target of 47,000, ensuring representation of underserved patient populations in cardiovascular research.
  • Environmental Impact: IQVIA achieved 100% My Green Lab certification for its global laboratory network, redesigned clinical trial test kits to use at least 98% recycled materials, and reduced packaging emissions in cold chain logistics by 70%, demonstrating its commitment to sustainable research.
Businesswire
2.0
02-27Businesswire
IQVIA Releases 2025 Sustainability Report Highlighting Progress
  • Sustainability Progress: IQVIA's 2025 Sustainability Report highlights advancements across its People, Public, and Planet pillars, demonstrating the company's commitment to accelerating innovation for a healthier world.
  • Global Workforce: With approximately 93,000 employees across over 100 countries, IQVIA enhances its capabilities in medical innovation and commercialization, leveraging expertise in healthcare, life sciences, and data science.
  • Privacy Protection Technologies: The company employs a variety of privacy-enhancing technologies to safeguard individual privacy while generating and analyzing data, enabling healthcare stakeholders to identify disease patterns and optimize treatment pathways.
  • Commitment to Responsible AI Use: IQVIA is dedicated to using AI responsibly, ensuring its AI capabilities meet high standards of privacy, compliance, and patient safety, thereby enhancing industry trust and service precision.
Barron's
4.5
02-27Barron's
Top and Bottom Performing S&P 500 Stocks in February
  • Stock Market Performance: The S&P 500 remained just below the 7000 mark throughout February, indicating a period of stagnation in the stock market.
  • Economic Concerns: Ongoing tariff issues and worries about the impact of artificial intelligence on the economy are contributing to the uncertainty in the stock market as March approaches.
Wall Street analysts forecast IQV stock price to rise
15 Analyst Rating
Wall Street analysts forecast IQV stock price to rise
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
215.00
Averages
258.31
High
290.00
Current: 0.000
sliders
Low
215.00
Averages
258.31
High
290.00
TD Cowen
Buy
maintain
$174 -> $213
AI Analysis
2026-03-09
New
Reason
TD Cowen
Price Target
$174 -> $213
AI Analysis
2026-03-09
New
maintain
Buy
Reason
TD Cowen raised the firm's price target on Iqvia to $213 from $174 and keeps a Buy rating on the shares. The firm does not see AI driving revenue headwinds for the company. While AI is likely to reduce drug trial costs by 10%-15%, the savings will be redeployed into additional activity, the analyst tells investors in a research note. TD sees an attractive risk/reward with Iqvia shares down 24% since the start of February.
TD Cowen
Hold
to
Buy
upgrade
$174 -> $213
2026-03-09
New
Reason
TD Cowen
Price Target
$174 -> $213
2026-03-09
New
upgrade
Hold
to
Buy
Reason
TD Cowen upgraded Iqvia to Buy from Hold with a price target of $213, up from $174. The firm does not see AI driving revenue headwinds for the company. While AI is likely to reduce drug trial costs by 10%-15%, the savings will be redeployed into additional activity, the analyst tells investors in a research note. TD sees an attractive risk/reward with Iqvia shares down 24% since the start of February.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IQV
Unlock Now

Valuation Metrics

The current forward P/E ratio for IQVIA Holdings Inc (IQV.N) is 17.87, compared to its 5-year average forward P/E of 20.24. For a more detailed relative valuation and DCF analysis to assess IQVIA Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
20.24
Current PE
17.87
Overvalued PE
23.99
Undervalued PE
16.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
14.55
Current EV/EBITDA
13.18
Overvalued EV/EBITDA
16.92
Undervalued EV/EBITDA
12.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.62
Current PS
2.28
Overvalued PS
3.09
Undervalued PS
2.14

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what are the best stocks right now
Intellectia · 72 candidates
Region: USAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10Pe Ttm: 10 - 35Return On Equity: >= 15.0%Is Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
SCHW logo
SCHW
Charles Schwab Corp
166.86B
GILD logo
GILD
Gilead Sciences Inc
178.68B
NXPI logo
NXPI
NXP Semiconductors NV
50.98B
WMB logo
WMB
Williams Companies Inc
90.69B
SYY logo
SYY
Sysco Corp
40.82B
IQV logo
IQV
IQVIA Holdings Inc
29.29B
rsi below 35 in the s&p500
Intellectia · 22 candidates
Rsi Category: oversoldIs Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
TMO logo
TMO
Thermo Fisher Scientific Inc
192.95B
CRM logo
CRM
Salesforce Inc
175.96B
ACN logo
ACN
Accenture PLC
147.75B
BKNG logo
BKNG
Booking Holdings Inc
137.64B
PANW logo
PANW
Palo Alto Networks Inc
124.32B
INTU logo
INTU
Intuit Inc
108.41B
what best stock to buy right now??
Intellectia · 92 candidates
Market Cap: >= 20.00BNet Margin: >= 10.00Eps 5yr Cagr: >= 10Pe Ttm: 10 - 35List Exchange: XNYS, XNASIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
SCHW logo
SCHW
Charles Schwab Corp
169.48B
BKNG logo
BKNG
Booking Holdings Inc
137.64B
GILD logo
GILD
Gilead Sciences Inc
189.55B
NXPI logo
NXPI
NXP Semiconductors NV
59.73B
KMI logo
KMI
Kinder Morgan Inc
71.84B
WFC logo
WFC
Wells Fargo & Co
273.88B
Best stocks to buy today
Intellectia · 6 candidates
Market Cap: >= 20.00BAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.66T
PCG logo
PCG
PG&E Corp
36.05B
AVGO logo
AVGO
Broadcom Inc
1.65T
AMD logo
AMD
Advanced Micro Devices Inc
352.35B
MDB logo
MDB
MongoDB Inc
29.34B
IQV logo
IQV
IQVIA Holdings Inc
31.80B
what options stock will go bearish today
Intellectia · 67 candidates
Volume: >= 300,000Price Change Pct: $-12.00 - $-0.50Moving Average Relationship: PriceBelowMA20Is Optionable: TrueOption Sentiments: Bearish
Ticker
Name
Market Cap$
top bottom
KMPR logo
KMPR
Kemper Corp
2.27B
IONQ logo
IONQ
IONQ Inc
12.07B
STE logo
STE
STERIS plc
26.01B
ARES logo
ARES
Ares Management Corp
43.20B
XRX logo
XRX
Xerox Holdings Corp
266.33M
NFE logo
NFE
New Fortress Energy Inc
369.92M

Whales Holding IQV

H
Hardman Johnston Global Advisors LLC
Holding
IQV
+18.55%
3M Return
B
Boston Partners Global Investors, Inc.
Holding
IQV
+9.82%
3M Return
I
Inspire Investing, LLC
Holding
IQV
+6.25%
3M Return
C
Cornerstone Investment Partners, LLC
Holding
IQV
+2.06%
3M Return
D
Diversified Trust Company, Inc.
Holding
IQV
+1.64%
3M Return
E
Empyrean Capital Partners, LP
Holding
IQV
+1.55%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is IQVIA Holdings Inc (IQV) stock price today?

The current price of IQV is 170.93 USD — it has decreased -4.27

What is IQVIA Holdings Inc (IQV)'s business?

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.

What is the price predicton of IQV Stock?

Wall Street analysts forecast IQV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IQV is258.31 USD with a low forecast of 215.00 USD and a high forecast of 290.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IQVIA Holdings Inc (IQV)'s revenue for the last quarter?

IQVIA Holdings Inc revenue for the last quarter amounts to 4.36B USD, increased 10.26

What is IQVIA Holdings Inc (IQV)'s earnings per share (EPS) for the last quarter?

IQVIA Holdings Inc. EPS for the last quarter amounts to 2.99 USD, increased 23.55

How many employees does IQVIA Holdings Inc (IQV). have?

IQVIA Holdings Inc (IQV) has 93000 emplpoyees as of March 11 2026.

What is IQVIA Holdings Inc (IQV) market cap?

Today IQV has the market capitalization of 28.69B USD.